VALBIOTIS
30.9.2021 07:37:05 CEST | Business Wire | Press release
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:ALVAL), a French research and development company committed to scientific innovation for preventing and combating metabolic diseases, publishes its financial report for the first half of 2021 and provides an update on the Company's progress.
Sébastien PELTIER, Chairman of the Board of Directors at Valbiotis, comments: "2020 was a pivotal year for Valbiotis with the conclusion of our strategic global partnership with Nestlé Health Science for TOTUM•63, our flagship product dedicated to the reduction of risk factors for type 2 diabetes. This partnership has decisively strengthened our visibility on an international scale. It has opened up promising marketing prospects for us as we enter the final phase of development of this active substance, which has already been scientifically proven to be effective. And, above all, it has strengthened our resolve to pursue our strategic roadmap. This is what 2021 is all about: redoubling our efforts to reach new milestones with TOTUM•63, as well as with the other products in our portfolio. In the first half of the year, we were on target. In addition to achieving new scientific milestones and strengthening our organization, we also secured our financial resources on a long-term basis. All of these achievements enable us to approach our next challenges with confidence, backed by the commitment of our employees and the crucial support of our shareholders. "
Main achievements since the beginning of 2021: start of the year perfectly in line with the roadmap
TOTUM•63, prediabetes
- Obtaining of Chinese patent
In the area of intellectual property, further progress was made in the first half of the year, with the granting of a patent in China for TOTUM•63. Announced in May 2021 (press release of May 19, 2021 ), this patent grants broad protection for the composition and use of this substance. It also confers a monopoly on exploitation in this strategic country, one of the most affected by metabolic diseases, where the prevalence of prediabetes in the adult population is estimated at 35%1 , i.e. 390 million people, and that of overweight and obesity at 50%2 . This is a concrete example of the Society’s global protection strategy, with patents having now been acquired in nearly 50 countries, including across Europe, the United States and China.
- First publications of scientific articles in three international journals
In line with the strategy developed with Nestlé Health Science, data on TOTUM•63 has been published in three international peer-reviewed journals, highlighting the focus on scientific promotion, which is decisive in preparing for future commercialization. These articles (press release of June 3, 2021 ) were published in the American Journal of Physiology-Endocrinology and Metabolism , the International Journal of Obesity and Nutrients . They constitute a validation by the scientific community of the work performed and allow the latter to better understand the mechanism of action of this active substance.
- Announcement of the implementation of a clinical mode of action study by INAF at Laval University in Quebec City (press release of June 28, 2021 )
On the scientific front, a new study co-designed by Valbiotis teams, INAF experts and Nestlé Health Science experts was also announced. It should provide additional data to support scientific communication and the marketing of this active substance. The launch of the study is planned for the fourth quarter of 2021.
TOTUM•070, reduction of LDL-hypercholesterolemia ("bad cholesterol")
- Launch of the HEART Phase II clinical study and First Patient First Visit
In February 2021 (press release of February 15, 2021), the company was authorized to launch the HEART Phase II clinical study and subsequently completed the First Patient First Visit (press release of February 22, 2021 ). The recruitment of the last volunteer in this study was announced at the beginning of September 2021 (press release of September 6, 2021 ), fully in line with the study's roadmap. Results are expected in the second quarter of 2022.
This study will evaluate the effect of TOTUM•070 on the reduction of LDL-cholesterol, a risk factor for cardiovascular disease, in people with mild to moderate hypercholesterolemia.
With the simultaneous launch of a clinical study to characterize all the metabolites and identify their effects in human cell models, as well as extensive preclinical work to be submitted to the American Heart Association (AHA) annual meeting in November 2021, this program will provide comprehensive data to position TOTUM•070 as a breakthrough innovation in the cardiovascular risk prevention market.
TOTUM•854, reduction of blood pressure
This program is seeing a strong acceleration in its development following the publication of positive preclinical results at the annual congress of the European Society of Hypertension (ESH) and the International Society of Hypertension (ISH) in April 2021 (press release of April 12, 2021
).
The Company announced the launch of a Phase II/III international, multicenter, randomized, placebo-controlled study in a population with mild to moderate blood pressure elevation. A second international, multicenter, randomized, placebo-controlled clinical study will be conducted in parallel. This strategy will allow Valbiotis to put together a complete health claim file. Finally, Valbiotis will conduct a third clinical study at the same time to measure the bioavailability of TOTUM•854, characterize its metabolites and explore their mode of action.
As the protocols are expected to be filed in the fourth quarter for results scheduled for the second half of 2023, acceleration of the program should allow commercialization as soon as Phase II/III results are available, up to 3 years ahead of the initial plan.
TOTUM•448, reduction of hepatic steatosis
The development strategy is being finalized. It will address the reduction of non-alcoholic hepatic steatosis, a condition that puts individuals at risk of developing NASH (“fatty liver disease”). A Phase II study should be initiated in the second half of the year.
Structuring of Marketing and Commercial Operations
During the first part of the year, strengthening the organization was also a priority. This was demonstrated in particular by the appointment of Sébastien BESSY as Chief Operating Marketing and Business Officer, responsible for the global deployment and coordination of the international strategy related to Valbiotis’ marketing and commercial development (press release of June 7, 2021
). Former Vice President Global Strategic Operations Consumer Healthcare at Ipsen, Sébastien BESSY brings his international expertise in Consumer Healthcare at a key time for the Company. He has more than 20 years of experience in international marketing strategy, commercial strategy, portfolio strategy and business development. Upon his appointment, Sébastien BESSY became a member of the Company's Board of Directors.
Obtaining of ISO-9001:2015 certification
The strengthening of the organization was also highlighted by the awarding of ISO-9001:2015 certification, issued by AFNOR, for all activities relating to "Design, development and production control of solutions for preventing and combating metabolic and cardiovascular diseases" (press release of March 22, 2021
). This certification guarantees expertise in all Discovery, Preclinical Research, Clinical Research, Production and Product Quality Management activities. Once again, this recognition constitutes a decisive asset in the pursuit of the strategy and the prospect of future market launches.
Financial information for the first half of 2021: a secure long-term financial position
The Company's half-yearly financial statements, prepared in accordance with IFRS, were approved by the Board of Directors on September 27, 2021. They have been subject to a limited review by the Statutory Auditor and are available on the Valbiotis website: www.valbiotis.com
(investors section).
IFRS in €K, at June 30 (1) |
First half of 2021 |
First half of 2020 |
Operating income Including: - Turnover - Grants - Research Tax Credit |
748
148
|
714
121
|
R&D expenditure |
(2 355) |
(1 939) |
Sales and Marketing expenditure |
(542) |
(545) |
Overhead expenditure |
(549) |
(638) |
Share-based payment expenditure |
(632) |
(226) |
Operating profit for the period |
(3 386) |
(2 557) |
Operating profit |
(3 386) |
(2 557) |
Earnings before tax |
(3 469) |
(2 830) |
Net profit |
(3 469) |
(2 931) |
|
||
IFRS in €K (1) |
First half of 2021 |
First half of 2020 |
Cash flow from operating activities |
(3 706) |
3 323 |
Cash flow from investing activities |
76 |
(101) |
Cash flow from financing activities |
14 865 |
(341) |
Net cash flow |
11 235 |
2 881 |
Cash flow |
25 820 |
10 914 |
For the first half of 2021, Valbiotis generated €748K of operating income, consisting mainly of the Research Tax Credit and revenue from the recognition of the share for the first half of 2021 of the upfront payment of CHF 5 million received under the partnership signed with Nestlé Health Science in February 2020.
Research and Development expenses increased by €416K, mainly due to the continuation of the Phase II/III REVERSE-IT clinical study on TOTUM•63 and the launch of the Phase II clinical study on TOTUM•070. The company also continued its preclinical research work at its technical platform in Riom.
Commercial and marketing expenditure remained stable at €542K and overhead expenditure decreased by €89K to €549K. This decrease is explained in particular by the finalization of the implementation of a new ERP system at the end of 2020.
During the first half of the year, cash flow from operating activities amounted to €3 706K reflecting the continuation and intensification of R&D activities. Cash flow from investing activities was positive at €76K, mainly due to the refinancing by the banking partner (lease back) of technical equipment for the Riom platform acquired during the second half of 2020 and the first half of 2021. Cash flow from financing activities was positive at €14 865K, mainly related to the capital increase by private placement in April 2021, for a gross amount of €15 million (press release of April 15, 2021 ), as well as to two loans obtained from Bpifrance for an amount of €1.3 million (press release of May 26, 2021 ).
At June 30, 2021, Valbiotis had a cash position of €25 820K, up nearly 77% compared to December 31, 2020.
To date, and taking into account in particular:
- Its available cash on June 30, 2021 amounting to €25 820K;
- Its operating expenses related to its current development plan;
- The maturity of its current financial debt;
- The upcoming receipt of the Research Tax Credit for the 2020 fiscal year in the amount of €1 257K (amount received in August 2021).
The Company has conducted a specific review of its liquidity risk and considers that it does not face any short-term risk. The cash flow horizon is therefore estimated at the first half of 2024 and does not take into account additional milestone payments that may be made by Nestlé Health Science or additional revenues that could come from new strategic partners.
Update on post-closing events
The month of September opened with the recruitment of the last volunteer in the Phase II HEART study conducted with TOTUM•070 for hypercholesterolemia (press release of September 6, 2021
). The completion of this recruitment confirms the announced schedule of the HEART clinical study, the results of which will be available in the second quarter of 2022. The HEART study is a key step in the development of TOTUM•070 and in the commercialization strategy for the non-drug hypercholesterolemia market, which is estimated at €1.2 billion in Europe and the United States3
.
In addition, Valbiotis announced the consolidation of its development of innovative natural health solutions, by integrating the exploration of microalgae produced in New Caledonia, through an exclusive agreement with ADECAL-Technopole and IFREMER (press release of September 29, 2021 ). This program should allow to develop a bank of high-potential strains selected by ADECAL-Technopole and IFREMER since 2013 in New Caledonia as part of the "AMICAL" joint research project.
About Valbiotis
Valbiotis is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, using a multi-target approach enabled by the use of terrestrial and marine plant-based resources.
Its products are intended to be licensed to players in the health sector.
Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and a subsidiary in Quebec (Canada).
Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.
For more information about Valbiotis, please visit: www.valbiotis.com
Name: Valbiotis
ISIN code: FR0013254851
Ticker symbol: ALVAL
EnterNext© PEA-PME 150
This press release contains forward-looking statements about Valbiotis’ objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as certain risks and uncertainties, including those described in the Valbiotis Universal Registration Document approved by the French Financial Markets Regulator (AMF) on July 27, 2021 (application number R 21-039). This document is available on the Company’s website (www.valbiotis.com
).
This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis’ shares or financial securities in any country.
1
Limin Wang et al. JAMA. 2017; 317(24):2515-2523
2
Chinese national nutrition and chronic disease report 2020, National Health Commission www.scienceetavenir.fr/sante/plus-d-un-chinois-sur-deux-desormais-en-surpoids_150360
(published on April 21, 2021)
3
AEC Partners Data, 2019, for Valbiotis
View source version on businesswire.com: https://www.businesswire.com/news/home/20210929005666/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OCP Announces Date of Third Quarter and Nine-Month 2026 Earnings19.11.2026 17:30:00 CET | Press release
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter and nine-month 2026 results on Monday, November 30, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 7:00 a.m. EDT, 12:00 p.m. Morocco and London time (GMT). OCP senior management will host a conference call to discuss third quarter and nine-month 2026 results at 8:00 a.m. EDT, 1:00 p.m. Morocco and London time (GMT) on Monday, November 30, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exclusive ac
ISACA Launches Updated COBIT 7 With Enhanced Assessment Model and Modern Digital Platform19.11.2026 16:24:00 CET | Press release
Refreshed framework reflects today’s technology landscape with streamlined design guidance, refreshed objectives and three levels of organizational assessment When AI can spark fears about humanity’s future and aging technology can bring air travel to a standstill, the cost of weak governance is impossible to ignore. To help enterprises strengthen the governance of their information and technology, ISACA has launched COBIT 7, an updated version of its globally recognized framework for information and technology (I&T) governance. Built for a rapidly changing digital world, the new COBIT 7 framework combines trusted guidance, an intuitive digital platform, customizable resources, and practical tools to help practitioners turn technology into measurable value, align decisions with strategy and confidently navigate emerging risks, including AI. COBIT 7 reinforces the framework’s longstanding role in helping businesses align their I&T operations with broader strategic goals, manage technolo
North Star Carbon Removal Project Selected by Government of Canada for Landmark Carbon Removal Procurement Program19.11.2026 16:04:00 CET | Press release
Microsoft-backed Saskatchewan project developed by MLTC and Svante among only three BECCS projects selected North Star, a planned large-scale carbon dioxide removal (CDR) project being developed by Meadow Lake Tribal Council (MLTC) and Svante Technologies Inc. (Svante), has been selected by the Government of Canada as a qualified supplier under the federal Request for Standing Offer (RFSO) for the Acquisition and Retirement of Credits from Carbon Dioxide Removal Projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118228180/en/ The proposed North Star bioenergy with carbon capture and storage project is being developed by the Meadow Lake Tribal Council (MLTC) and Svante. The project will generate durable carbon dioxide removal credits by capturing biogenic CO2 from the MLTC Bioenergy Center in Meadow Lake, SK, Canada, and storing it deep underground in a geological storage site. North Star was one of only three bioene
Xsolla Gives Games a New Home for Their Players on Desktop and the Web, With Rewards to Help Bring Players Back19.11.2026 15:32:00 CET | Press release
Developers Can Now Reach Players on Desktop and the Web With Xsolla Player and Xsolla Pages Xsolla (USA), Inc., a global commerce company, is giving game developers two new capabilities designed to reach players and encourage repeat engagement. Xsolla Player and Xsolla Pages are now available, letting developers integrate quests, rewards, and partner-funded offers into the player flow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119175727/en/ Graphic: Xsolla Xsolla Player is a desktop app that players install once and access with their Xsolla ID, bringing their game library and inventory together without separate sign-ups for each game. Xsolla Pages creates search-optimized storefronts on the web for every title in a developer’s catalog, with direct checkout. PC studios work hard to win a player's first click, then work just as hard for every session after. Bringing players back is a challenge and has traditionally req
From London 1851 to Riyadh 2030: The United Kingdom Continues Its World Expo Legacy with the Signing of Its Participation Contract for Expo 2030 Riyadh19.11.2026 15:10:00 CET | Press release
The United Kingdom has signed its Participation Contract for Expo 2030 Riyadh, confirming its place at one of the world’s largest global gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119617914/en/ The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State for Foreign Affairs, Climate Envoy, and Commissioner General of Expo 2030 Riyadh; and Lord Sarwar, UK Minister for Trade; and Talal Al-Marri, CEO of Expo 2030 Riyadh. The Agreement constitutes a significant milestone in the United Kingdom’s journey towards Expo 2030 Riyadh, establishing the framework for the execution of its pavilion, programming and visitor experience. This latest agreement adds to a growing number of Participation Contract signings, reflecting increasing momentum behind Expo 2030 Riyadh and the value countries are placing on being part of it. The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
